Trump's surgeon general pick exposes cracks in MAHA movement
Casey Means is a prominent health influencer and ally of Health and Human Services Secretary Robert F. Kennedy Jr., but she is seen as insufficiently skeptical of vaccines by some of his prominent supporters — and a 'total crack pot' by others in Trump World.
Trump chose the Stanford-educated doctor-turned-chronic disease entrepreneur to be surgeon general after withdrawing his first pick Janette Nesheiwat, a former physician and Fox News host. Means, like Kennedy, has focused much of her health advocacy on diet and nutrition.
'Bobby really thought she was great. I don't know her. I listened to the recommendation of Bobby,' Trump said of Means. 'I met her yesterday and once before. She's a very outstanding person. A great academic, actually. So I think she'll be great.'
Nesheiwat's nomination was withdrawn the day before her Senate confirmation hearing, after media reports called her credentials into question and conservative figures attacked her for praising the COVID-19 vaccines.
Like Kennedy, Means has expressed skepticism about vaccines, promotes food as medicine and is critical of the current health care system. But the pick was unpopular with other health influencers aligned with Kennedy.
'I can't help but think this is a very carefully groomed and selected person. Just about no clinical experience. Talks a great game about everything but vaccines. Feels all wrong,' said Suzanne Humphries, a medical researcher who, like Means, has appeared on Joe Rogan's podcast.
'She's not a health freedom advocate,' Mike Adam, who goes by Health Ranger, wrote on social platform X. 'She's not a vaccine truther. She'll never recommend natural cancer cures or remedies. She's basically cosplaying as a MAHA champion.'
Means became a key influence in the MAHA movement last year along with her brother Calley Means, who works as an adviser to Kennedy in Department of Health and Human Services.
They co-wrote the book 'Good Energy: The Surprising Connection Between Metabolism and Limitless Health' about the connection between metabolism and personal health, and they promoted their ideas across conservative media, including a hit episode of Tucker Carlson's podcast.
The blowback to her nomination reflects the broader tensions within the MAHA movement, as different factions vie for influence in the Trump administration. The surgeon general serves as the public health face of the administration and wields a powerful bully pulpit, but has little actual authority.
Richard Carpiano, a professor of public policy at the University of California, Riverside, researches social factors affecting vaccine uptake and the anti-vaccine movement. He said Casey Means seems to have failed the purity test among some Kennedy supporters, but that public infighting also reflects the realities and limits MAHA.
'This is really kind of showing or pointing to questions of, you know, to what degree is it really like a movement or is it really just this kind of like brand that that Kennedy is really just trying to push,' Carpiano said.
MAGA influencer Laura Loomer in a series of posts on X accused the president's advisers of poorly vetting the new nominee for surgeon general.
She called Means a 'total crack pot' and 'Marxist tree hugger,' in the post, pointing to various alternative practices Means has written about, including communicating with spirit mediums and using hallucinogenic mushrooms as medicine.
Kennedy's former running mate, Nicole Shanahan, has also criticized Means's nomination, writing in a post on X that she was told neither of the Means siblings would work at department if she supported Kennedy.
'With regard to these siblings, there is something very artificial and aggressive about them, almost like they were bred and raised by Manchurian assets,' she wrote, adding that she suspected Kennedy was being controlled.
Kennedy has vehemently defended Means's nomination.
'The absurd attacks on Casey Means reveal just how far off course our healthcare conversations have veered, and how badly entrenched interests–including Big Food and its industry-funded social media gurus–are terrified of change,' he wrote Thursday on X.
Calley Means on Friday shot back at Loomer, writing on X, 'Just received information that Laura Loomer is taking money from industry to scuttle President Trump's agenda. @LauraLoomer if that's incorrect, sue me and let's do discovery.'
Loomer responded by calling him a 'PR spin master' and accused him of being 'threatened' by her 'access to President Trump.'
Casey Means left a five-year residency program at the Oregon Health & Science University after 4 1/2 years due to anxiety and feeling she wanted to do something different, the Los Angeles Times reported.
She has since cultivated a large following online and is the co-founder of Levels, a health technology company that focuses on tracking health information through devices like continuous glucose monitors.
Those who've worked with Means describe her as someone with a genuine concern for public health, particularly when it comes to young people.
Soh Kim, executive director of the Stanford Center for Innovation and Design Research, worked alongside Means at Stanford University, teaching a food, design and technology course.
'She is very rare in terms of, like, her rigorous medical knowledge but also, she is somebody who can, you know, talk to anyone in the class with their level,' Kim said.
But others questioned her qualifications for such a high-profile public health role. Former U.S. Surgeon General Jerome Adams noted, shortly after Means was nominated, that the surgeon general position has historically been required to be held be a licensed physician.
'As the Senate is considering confirmation, it is important that historical precedent, the ability to effectively lead the USPHS, and the law, are all taken into consideration,' he wrote, referring to the U.S. Public Health Service, which the surgeon general oversees.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
3 hours ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
3 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know
Epoch Times
4 hours ago
- Epoch Times
Kentucky Church Brings Pandemic-Era Legal Dispute to Supreme Court
A Kentucky church is asking the Supreme Court to decide if the state government must pay its legal expenses from a challenge to COVID-19-era restrictions on church attendance. The church is arguing that its constitutional rights were violated when it was denied attorney's fees in its lawsuit, after the same court awarded those fees to litigants in another lawsuit based on the same facts.
